Myocardial delivery of miR30d with peptide-functionalized milk-derived extracellular vesicles for targeted treatment of hypertrophic heart failure

Quick Facts

• Publication title: Myocardial delivery of miR30d with peptide-functionalized milk-derived extracellular vesicles for targeted treatment of hypertrophic heart failure
• Journal: Biomaterials
• Year: 2024
• DOI: 10.1016/j.biomaterials.2024.122976
• PMID/PMCID: 39637583

Research overview

Mechanistically, we identified GRK5 as an unprecedented target of miR30d in cardiac hypertrophy. However, effective delivery of miR30d to the heart is challenging.

Key findings

miR30d has been shown to reverse cardiac hypertrophy.

However, effective delivery of miR30d to the heart is challenging.

Here, we engineered milk-derived extracellular vesicles (mEVs) by surface functionalization with an ischemic myocardium-targeting peptide (IMTP) and encapsulated miR30d to develop a formulation, the miR30d-mEVsIMTP, enabling targeted delivery of miR30d to the injured heart.

In vitro, the miR30d-mEVsIMTP can be effectively internalized by hypoxia-induced H9C2 cells via the endo-lysosomal pathway.

Echo Biotech Role

Echo Biotech contributed cargo loading; the study also used or cited ExoLoad®.

Related platforms: Echosome®, Research Reagents & Tools

Related services and capabilities: Small RNA / Cargo Loading, Research Reagent / Product Supply

Related products or reagents: ExoLoad® Nucleic Acid Loading Kit

References

Original publication: Myocardial delivery of miR30d with peptide-functionalized milk-derived extracellular vesicles for targeted treatment of hypertrophic heart failure Biomaterials. 2024. DOI: 10.1016/j.biomaterials.2024.122976. PMID/PMCID: 39637583.